Because GLP-2 acts through subepithelial myofibroblasts, which are the same cell population implicated in intestinal fibrogenesis, the risk-benefit profile of GLP-2 agonism may differ substantially between mucosal UC, inflammatory ileal CD, and stricturing or penetrating CD phenotypes, and this phenotypic stratification should be a required feature of future trial design
Chewable formulations may improve compliance, though proper storage and education are essential
The safest peptide options for women guide discusses tolerance considerations that often favor lower maintenance doses, and the peptides for men guide covers male-specific factors in dose selection
While this savings program is now officially available, experts say most Americans will likely not benefit from it
So these two tests, along with the history, are frequently enough to justify treatment